Tirzepatide Zepbound vs Mounjaro: same molecule, two brand names. Here's why both exist, what the trials measured, and what changes in your routine.

One molecule, two brand names

If you've searched for tirzepatide Zepbound vs Mounjaro, you've probably noticed that the names look like two different drugs. They aren't. Both brands contain tirzepatide, a single active ingredient made by Eli Lilly and Company. Tirzepatide is a dual agonist, which means it activates two gut hormone receptors at the same time: GIP and GLP-1. Our earlier article on GLP-1 and GIP receptors covers that biology in depth, so here we'll stay focused on what matters when you choose and use the product.

The mechanism of action doesn't change between the Mounjaro and Zepbound names. If you're just starting out, MounjaBlog gathers plain-language explainers on tirzepatide, and the difference between brand names is a good question to settle early.

Same active ingredient doesn't mean identical product, though. Excipients, pen design, available strengths, packaging, and the leaflet text can all differ depending on the brand and the country. The molecule is shared, but the box in your hand is its own product, and the leaflet inside it is the document to trust most.

Why the same drug got two labels

Doctor consults with patient in medical office

Each brand was approved for a different indication, at a different time, by a different regulator. Mounjaro came first. The U.S. Food and Drug Administration approved it in May 2022 for adults with type 2 diabetes, as an add-on to diet and exercise. Zepbound followed in November 2023 for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition.

Approval and prescribing are not the same thing. A doctor can sometimes prescribe a medicine for a use outside its approved indication when they judge it appropriate. That's called off-label use. It's a clinical decision, and your doctor should explain the reasoning to you directly. It isn't a loophole, and it doesn't mean the product has been approved for that purpose.

Approved indications also change from country to country, and Brazil is no exception. Registration status can be updated over time, so check the current ANVISA information for the exact indication before assuming that either brand covers your situation.

What the trials measured in each population

The clinical work behind these brands comes from two separate programs. The SURPASS program studied tirzepatide in adults with type 2 diabetes, and its main glycemic trials used change in hemoglobin A1c as the primary outcome, a measure of average blood sugar over roughly three months. The SURMOUNT program studied tirzepatide in adults with obesity, and its primary outcome was change in body weight. SURMOUNT-1 enrolled people without type 2 diabetes, so the populations really do differ.

That difference matters. Comparing numbers across the two programs is a bit like comparing apples to oranges, because the populations, endpoints, doses, and follow-up periods are not the same. The SURMOUNT-1 results were published in the New England Journal of Medicine, and that article is the place to see the exact design.

So read the full publication before you quote any percentage. Look at who was enrolled, which doses were tested, how long participants were followed, and how the results were analyzed. I'm deliberately leaving out specific figures here, because a number pulled from a summary can easily lose its context.

What changes at the pharmacy and in the pen

The weekly routine is the same for both names. You inject tirzepatide under the skin once a week, and the dose goes up gradually. The Mounjaro leaflet describes a starting dose of 2.5 mg once weekly, with increases in 2.5 mg steps made at least four weeks apart, based on how you respond and tolerate the medicine.

Presentations can vary by country. Some markets offer a pen, others offer vials, and the available strengths are not always the same. Read the label on the box before you leave the pharmacy. Confirm the brand name, the strength, and the number of doses. If something doesn't match your prescription, ask before you open anything.

Storage matters too. Keep unused pens refrigerated before the first use, and never freeze them. After the first use, follow the time limit printed in the leaflet, since that window can differ between products.

Access is the part that varies most. Insurance coverage depends on your plan and the indication, some manufacturer support programs exist in certain countries, and availability is uneven across markets. Buy only through official channels in your country. I won't quote prices, because they change often and differ by region. When you need a refresher on reading labels and pen markings, MounjaBlog has a guide you can keep beside your prescription.

Safety warnings that do not change between names

Tirzepatide carries a boxed warning about a risk of thyroid C-cell tumors, including medullary thyroid carcinoma. The leaflet explains that this warning comes from studies in rodents, and that it is not known whether tirzepatide causes these tumors in people. Because of that uncertainty, tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

The leaflet lists other points of attention too. Pancreatitis, gallbladder problems, and dehydration with acute kidney injury can occur, especially when vomiting or diarrhea is severe. Hypoglycemia is more likely when tirzepatide is combined with insulin or a sulfonylurea, so your doctor may adjust those medicines.

Contraception and pregnancy planning also need attention. Tirzepatide can reduce how well oral hormonal contraceptives work, and the leaflet gives specific guidance on backup methods after starting and after each dose increase. It also describes how long to stop the medicine before trying to conceive, so ask your doctor for the exact timing.

Seek urgent care for severe abdominal pain that may radiate to your back, vomiting that won't stop, a lump or swelling in the neck, trouble swallowing, or signs of dehydration such as dizziness and very low urine output. The risk profile is the same regardless of brand, because the active ingredient is the same.

How to talk with your doctor about the right label

Bring the exact brand name, the dose, and the indication written on your prescription to every appointment. If the prescription says one name and the box says another, ask about it right away. Don't assume the pharmacy made a mistake, and don't assume it didn't.

Be careful with compounded or unregistered versions. A product made outside the approved registration isn't the same as the approved product, and its dose, purity, and quality can't be checked the way they can for a registered medicine. ANVISA's consultation portal lets you check whether a medicine is registered in Brazil before you start.

When you talk with your doctor, these three questions help:

Which indication is this prescription based on, and is it on-label or off-label?
What happens if my plan doesn't cover the medicine, and are there other options?
How will my weight and blood sugar be monitored, and how often?

The leaflet points to blood glucose checks when tirzepatide is used with diabetes medicines, kidney function monitoring if vomiting or diarrhea persists, and attention to gastrointestinal symptoms. For a broader set of plain explainers on these topics, the MounjaBlog content library is a good place to prepare questions before your appointment.

Choosing a brand and a dose is a decision you make with your doctor, based on your health history, your goals, and your coverage. It's not something to settle by comparing online posts, including this one.

FAQ

Is Zepbound the same as Mounjaro?

They contain the same active ingredient, tirzepatide, and work through the same mechanism. The brands differ in approved indications, packaging, and sometimes in the leaflet and available strengths, so the product you receive may not look identical.

Can I use Mounjaro for weight loss?

Doctors can sometimes prescribe a medicine outside its approved indication when they judge it appropriate. That's off-label use. Ask your doctor which indication the prescription is based on, and what that means for your coverage and monitoring.

How often is tirzepatide taken?

It's injected under the skin once a week. The Mounjaro leaflet describes starting at 2.5 mg, with the dose increased gradually in steps made at least four weeks apart.

Does the thyroid boxed warning apply to both brands?

Yes, because the active ingredient is the same. If you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, tirzepatide should not be used, so tell your doctor about your history before starting.

Sources